TACSTD2 and breast carcinoma: Regarding TROP2-directed ADCs, Dato-DXd has been approved in patients with HR-positive, HER2-negative (IHC 0, IHC 1+, IHC2+/ISH−) breast cancer who had previously had ET and chemotherapy [62,63,64].